Taiwan has targeted advanced therapy as its key element for biomedical industry development. Besides a well-established infrastructure and biomedical clusters, Taiwanese government has launched regulations to promote cell therapies. Therapies would be performed including autologous CD34 + selection peripheral blood stem cell transplantation, autoimmune cell therapy, autologous adipose stem cell transplantation, autologous fibroblast transplantation, autologous bone marrow mesenchymal stem cells, and autologous chondrocyte transplantation. Medical centers will participate to trials and treatments for advanced therapies. This would benefit some 100,000 patients annually in Taiwan and make Taiwan an ideal partner to develop regenerative medicine and cell therapy. This presentation will update the progress for the advanced therapies and the ecosystem in Taiwan including incentives for advancing together with Taiwanese partners.